QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - NYSE:QGEN - NL0015002CX3 - Common Stock
44.13 USD
-0.19 (-0.43%)
43.74 USD
-0.39 (-0.88%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 58 industry peers in the Life Sciences Tools & Services industry. QGEN gets an excellent profitability rating and is at the same time showing great financial health properties. QGEN has a correct valuation and a medium growth rate. With these ratings, QGEN could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
QGEN had a positive operating cash flow in the past year.
QGEN had positive earnings in each of the past 5 years.
In the past 5 years QGEN always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 6.19%, QGEN belongs to the best of the industry, outperforming 82.76% of the companies in the same industry.
QGEN has a Return On Equity of 11.11%. This is amongst the best in the industry. QGEN outperforms 82.76% of its industry peers.
With a decent Return On Invested Capital value of 7.44%, QGEN is doing good in the industry, outperforming 79.31% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 13.56%.
The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(7.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
QGEN's Profit Margin of 19.58% is amongst the best of the industry. QGEN outperforms 94.83% of its industry peers.
QGEN's Profit Margin has declined in the last couple of years.
The Operating Margin of QGEN (27.02%) is better than 96.55% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
QGEN has a Gross Margin of 64.10%. This is amongst the best in the industry. QGEN outperforms 86.21% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
Compared to 5 years ago, QGEN has less shares outstanding
Compared to 1 year ago, QGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.43 indicates that QGEN is not in any danger for bankruptcy at the moment.
QGEN's Altman-Z score of 3.43 is fine compared to the rest of the industry. QGEN outperforms 74.14% of its industry peers.
QGEN has a debt to FCF ratio of 4.50. This is a neutral value as QGEN would need 4.50 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.50, QGEN is doing good in the industry, outperforming 72.41% of the companies in the same industry.
QGEN has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: QGEN underperforms 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.43 |
ROIC/WACC0.93
WACC7.97%
2.3 Liquidity
A Current Ratio of 2.60 indicates that QGEN has no problem at all paying its short term obligations.
QGEN has a Current ratio (2.60) which is comparable to the rest of the industry.
QGEN has a Quick Ratio of 2.30. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
QGEN has a Quick ratio of 2.30. This is comparable to the rest of the industry: QGEN outperforms 51.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.40% yearly.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.32%.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.32% on average per year.
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
Based on estimates for the next years, QGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.80% on average per year.
QGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.89% yearly.
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
QGEN is valuated rather expensively with a Price/Earnings ratio of 18.62.
QGEN's Price/Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 89.66% of the companies in the same industry.
QGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 25.56, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 17.00, which indicates a rather expensive current valuation of QGEN.
87.93% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.62, QGEN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 17 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaper than 93.10% of the companies in the same industry.
QGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. QGEN is cheaper than 86.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.25 | ||
| EV/EBITDA | 12.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.18
PEG (5Y)2.22
EPS Next 2Y8.08%
EPS Next 3Y8.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.56%, QGEN is not a good candidate for dividend investing.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.48. QGEN pays more dividend than 94.83% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
5.2 History
QGEN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.08%
EPS Next 3Y8.5%
44.13
-0.19 (-0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change-18.51%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.57B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts74.17
Price Target52.09 (18.04%)
Short Float %2.86%
Short Ratio5.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.56% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-0.56%
PT rev (3m)1.07%
EPS NQ rev (1m)-0.68%
EPS NQ rev (3m)-1.53%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)-1.02%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 17 | ||
| P/S | 4.62 | ||
| P/FCF | 20.25 | ||
| P/OCF | 14.55 | ||
| P/B | 2.62 | ||
| P/tB | 11.99 | ||
| EV/EBITDA | 12.91 |
EPS(TTM)2.37
EY5.37%
EPS(NY)2.6
Fwd EY5.88%
FCF(TTM)2.18
FCFY4.94%
OCF(TTM)3.03
OCFY6.87%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.18
PEG (5Y)2.22
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.43 |
F-Score8
WACC7.97%
ROIC/WACC0.93
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
What is the valuation status of QIAGEN N.V. (QGEN) stock?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?
The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 18.62 and the Price/Book (PB) ratio is 2.62.